%0 Journal Article
%A Vishwanathan, Karthick
%A Sanchez-Simon, Inmaculada
%A Keam, Bhumsuk
%A Penel, Nicolas
%A de Miguel-Luken, Maria
%A Weilert, Doris
%A Mills, Andrew
%A Marotti, Marcelo
%A Johnson, Martin
%A Ravaud, Alain
%T A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
%D 2020
%U http://hdl.handle.net/10668/15791
%X Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. In this phase I study, we assessed the effects of normal renal function (NRF) and severe renal impairment (SRI) on the pharmacokinetics (PK) of osimertinib in patients with solid tumors. Part A: patients with NRF (creatinine clearance [CrCL] ≥90 mL/min), and SRI, (CrCL
%K epidermal growth factor receptors
%K kidney
%K non-small cell lung cancer
%K osimertinib
%K pharmacokinetics
%K renal disposition
%K tyrosine kinase inhibitors
%~